General Updates

9th September 2026 IOLCP/CGC/2026 National Stock Exchange of India Ltd BSE Limited Exchange Plaza, Plot no. C/1, G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (E) Dalal Street Mumbai - 400 051 Mumbai – 400 001 Security Symbol: IOLCP Security Code: 524164 Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Expansion of Ibuprofen Capacity, New CDMO Business for Pharmaceutical Formulations and Dedicated Specialty Chemicals Manufacturing Facility Dear Sir, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated 30th January 2026, we wish to inform that the Company has undertaken the following key business and capacity expansion initiatives, aimed at strengthening its manufacturing capabilities, broadening its product and service portfolio and supporting its long-term growth strategy: 1. Expansion of Ibuprofen Capacity: The Company is setting up a fully backward-integrated, state-of-the-art new manufacturing unit for Ibuprofen at its existing site at Barnala, Punjab, with an installed manufacturing capacity of 6,000 MT per annum, which will enhance the Company’s existing Ibuprofen manufacturing capacity from 12,000 MT per annum to 18,000 MT per annum upon commissioning of the new unit. The estimated project cost is approximately ₹350 Crore, which is proposed to be funded through internal accruals. Details required under abovesaid SEBI Master Circular is annexed herewith as “Annexure -1”. 2. CDMO for Pharmaceutical Formulations: The Company has installed a new pharmaceutical formulation manufacturing facility at its existing site at Barnala, Punjab, diversifying into Contract Development and Manufacturing Organisation (“CDMO”) for Pharmaceutical Formulations as a new line of business. The facility has an installed capacity of approximately 1,500 million tablets per annum or equivalent volume of Direct Compressible Grade and has been established at an estimated project cost of approximately ₹110 Crore, funded entirely through internal accruals. The new line of business has been established primarily to cater to the evolving and long-term contract manufacturing requirements of the Company’s Anchor Customers in European region, leveraging its existing manufacturing capabilities, quality standards, regulatory compliance and technical expertise. This represents a customer-led and complementary extension of the Company’s existing API business. The facility has successfully completed the requisite regulatory inspection and received the Certificate of GMP Compliance of a Manufacturer (GMP Certificate) from the National Centre for Public Health and Pharmacy, Directorate for Drug Inspection, Hungary. The facility is expected to be commercialized during the Q3 FY 2027. The initiative is expected to strengthen long-term customer relationships and create additional opportunities across the pharmaceutical value chain. 3. Establishing Dedicated Specialty Chemicals Manufacturing Facility under Long-Term Tolling Arrangement: The Company is establishing a dedicated manufacturing facility for the manufacture of the Specialty Chemical Product for a Leading Global Chemical Company under a long-term tolling arrangement. The project entails an estimated capital expenditure of approximately ₹35 Crore, to be funded through internal accruals. The facility will be dedicated to fulfilling the customer’s long-term requirements under the tolling arrangement. The facility is expected to be commercialized during the Q3 FY 2027. Details required under abovesaid SEBI Master Circular is annexed herewith as “Annexure -2”. This is for your information & record. Thanking You, Yours faithfully, for IOL Chemicals and Pharmaceuticals Limited Abhay Raj Singh Sr. Vice President & Company Secretary Annexure – 1 Details required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026, is annexed herewith Product Name Ibuprofen Existing capacity; 12,000 MTPA Existing capacity utilization; 95% Proposed capacity addition; 6,000 MTPA Period within which the proposed Expected to be commercialized by December 2027 capacity is to be added; Investment required; About Rs. 350 Cr Mode of financing; Internal accruals Rationale The capacity expansion is being undertaken to address the growing global demand for Ibuprofen and reinforce the Company’s established position as a leading global manufacturer of Ibuprofen. The expansion is also aligned with the ongoing business development and customer engagements across various international markets, reflecting increasing opportunities for the Company’s Ibuprofen business. Supported by its backward-integrated manufacturing platform, established global customer base and proven manufacturing capabilities, the additional capacity will enhance the Company’s ability to meet evolving customer requirements, strengthen supply reliability and support long-term growth in the Ibuprofen business. Annexure -2 Details required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026 1 Name of the entity with A leading global chemical company. whom agreement is signed 2 Area of agreement Long-term manufacturing and supply of specialty chemicals. 3 Domestic / International International. 4 Share exchange ratio Not applicable. 5 Scope of business operation Manufacturing and supply of Specialty Chemicals (the of the agreement “Product”) by the Company for the customer in accordance with the agreed terms. 6 Details of consideration paid The arrangement is expected to contribute materially to the / received in the agreement Company’s revenue stream upon commencement of commercial supplies. 7 Significant terms and The Company will manufacture and supply the Product conditions of the agreement exclusively for the customer in accordance with the mutually in brief agreed terms. In view of the confidentiality obligations agreed between the parties, the Company is restricted from disclosing the identity of the customer and quantitative/commercial details of the arrangement. The estimated capital expenditure for establishing a dedicated manufacturing facility for the Product is approximately ₹35 Crore, which is proposed to be funded through the Company’s internal accruals. 8 Whether the acquisition Not applicable. The transaction does not constitute an would fall within related acquisition. Further, the customer is not a related party of the party transactions and Company. whether the promoter/promoter group/group companies have any interest in the entity being acquired 9 Size of the entity(ies) Not applicable. 10 Rationale and benefit It is expected to provide a stable and reliable long-term expected demand for the Product, strengthen the Company’s manufacturing capabilities and expand its presence in the specialty chemicals and contract manufacturing segment for sustainable long-term growth of the Company